**Innovation at Work**

**Minnesota**

- **Total Direct and Indirect Economic Output of the Biopharmaceutical Sector**: $11.9 billion
- **Total Employment Supported by the Biopharmaceutical Sector**: 53,866
- **Percentage of Minnesotans 65 and older who were reported as disabled in 2014**: 30.8%
- **Total NIH Award Funding (FY16)**: $520 million

**Local Perspective: Minneapolis, MN**

“I support research because it gives us hope. Hope for a future without the physical and emotional pain of disease. Hope that no patients or families will have to experience the heartbreak of a diagnosis. Hope that my mom will live to see her grandchildren. Research is the master key to finding a cure.”

- Grant Niver, 27

**Research in the North Star State**

**University of Minnesota, Minneapolis, MN**

National Institutes of Health (NIH) funded researchers at the University of Minnesota are working on harnessing the body’s capabilities to kill cancerous tumors. The study uses immunotherapy to treat malignant melanoma, an aggressive form of cancer that usually results in death less than 9 months after diagnosis.

**Mayo Clinic, Medtronic, University of California, Los Angeles (UCLA), Reneu Health, Bel13ve**

This diverse collaboration is conducting phase I clinical trials testing the safety and efficacy of an epidural stimulator to help restore movement for patients with spinal cord injury.

**Boston Scientific, Minneapolis and St. Paul, MN**

Boston Scientific researchers have observed during clinical trials that HeartLogic, an implanted device for patients with heart failure, may be highly useful in predicting future heart conditions.

**Sources:** National Institutes of Health, Pharmaceutical Research and Manufacturers of America (PhRMA), Centers for Disease Control and Prevention, A ResearchAmerica Survey of U.S. Adults Conducted in Partnership with Zogby Analytics in June 2016, Boston Scientific, ClinicalTrials.gov.